Evidence map›Paper›PMID 23873072›Full record

ArticleEpidemiology (Cambridge, Mass.)2013

Antidepressant use and risk for preeclampsia.

Kristin Palmsten, Krista F Huybrechts, Karin B Michels, Paige L Williams, Helen Mogun, Soko Setoguchi, Sonia Hernández-Díaz

Open access · greenAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Epidemiology (Cambridge, Mass.), 2013. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 40 papers, 8 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
40citing papers in PubMed, 8 pooled it
8.5field-weighted citation impact, top 2% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

40 citing papers in PubMed, 8 syntheses or guidelines pooled it, 103 citations in OpenAlex.

  1. Pooled it
  2. Pooled it
  3. Pooled it
  4. Pooled it
  5. Pooled it
  6. Pooled it
  7. Pooled it
  8. Pooled it
  9. Trial
  10. Sex-specific considerations in migraine therapy.Neurotherapeutics : the journal of the American Society for Experimental NeuroTherapeutics · 2026
    Review
  11. Article
  12. Review
  13. Article
  14. Article
  15. Article
  16. Article
  17. Article
  18. Article
  19. Review
  20. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

7 authors at 4 institutions in 2 countries.

Kristin PalmstenDepartment of Epidemiology, Harvard School of Public Health, Boston, MA 02115, USA. kkp762@mail.harvard.edu
Krista F Huybrechts
Karin B Michels
Paige L Williams
Helen Mogun
Soko Setoguchi
Sonia Hernández-Díaz
Harvard University · USBrigham and Women's Hospital · USClinical Research Institute · USUniversity of Freiburg · DE

Funding

Comparative Effectiveness and Safety of Depression Treatments during PregnancyR01HS018533 · AHRQ · HARVARD SCHOOL OF PUBLIC HEALTH · PI HERNANDEZ-DIAZ, SONIA · 2009 to 2013
$2.2M
Predictors of Mammary Gland Development & Breast Fibroglandular Volume at pubertyR01CA158313 · NCI · UNIVERSITY OF CALIFORNIA LOS ANGELES · PI MICHELS, KARIN B · 2012 to 2015
$1.9M
Predoctoral Training Program in Reproductive, Perinatal & Pediatric EpidemiologyT32HD060454 · NICHD · HARVARD SCHOOL OF PUBLIC HEALTH · PI MICHELS, KARIN B · 2010 to 2014
$1.1M
Improving Methods for Comparative Effectiveness Research in Cardiovascular CareK02HS017731 · AHRQ · DUKE UNIVERSITY · PI SETOGUCHI IWATA, SOKO · 2008 to 2012
$752k
AHRQ HHS K02 HS017731AHRQ HHS K02HS017731AHRQ HHS R01 HS018533AHRQ HHS R01HS018533NCI NIH HHS R01 CA158313NICHD NIH HHS T32 HD060454NICHD NIH HHS T32HD060454
6 · The paper itself

Abstract

backgroundPrior studies suggest that women who use antidepressants during pregnancy have an increased risk for preeclampsia, yet the comparative safety of specific antidepressants remains unclear. US nationwide Medicaid Analytic eXtract (MAX) data have not been used to study medication safety during pregnancy.

methodsWe identified 100,942 pregnant women with depression from 2000 to 2007 MAX data. We used pharmacy dispensing records to ascertain exposure to selective serotonin reuptake inhibitor (SSRI), serotonin-norepenephrine reuptake inhibitor (SNRI), tricyclic, bupropion, other antidepressant monotherapy or polytherapy, and specific antidepressants, during the second trimester and first half of the third trimester. Relative risks (RRs) and 95% confidence intervals (CIs) were adjusted for delivery year, preeclampsia risk factors, depression severity proxies, other antidepressant indications, other medications, and healthcare utilization.

resultsThe risk of preeclampsia was 5.4% among women with depression and no antidepressant exposure. Compared with these women, the risk for preeclampsia was higher among those receiving SNRI (RR: 1.52, 95% CI = 1.26-1.83) and tricyclic monotherapy (RR: 1.62, 95% CI = 1.23-2.12), but not SSRI monotherapy (RR: 1.00, 95% CI = 0.93-1.07) or other antidepressants. Compared with women receiving SSRI monotherapy, preeclampsia risk was higher among women with SNRI (RR: 1.54, 95% CI = 1.28-1.86) and tricyclic (RR: 1.64, 95% CI = 1.25-2.16) monotherapy. None of the specific SSRIs was associated with preeclampsia. The RR with venlafaxine was 1.57 (95% CI = 1.29-1.91) and with amitriptyline 1.72 (95% CI = 1.24-2.40).

conclusionsIn this population, SNRIs and tricyclics were associated with a higher risk of preeclampsia than SSRIs.

Indexed as

AdultAntidepressive AgentsAntidepressive Agents, TricyclicDatabases, FactualDepressionFemaleHumansMedicaidPre-EclampsiaPregnancyPregnancy Trimester, SecondPregnancy Trimester, ThirdRisk AssessmentSelective Serotonin Reuptake InhibitorsUnited StatesAntidepressive AgentsAntidepressive Agents, TricyclicSelective Serotonin Reuptake Inhibitors

Identifiers

PMID23873072
PMCPMC4159745
OpenAlexW2003924756

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.